Last updated: February 19, 2026
What Is the Scope of Patent EP3692021?
Patent EP3692021 is granted by the European Patent Office (EPO) and covers a pharmaceutical invention. Its scope primarily relates to a specific drug formulation, method of manufacturing, or therapeutic use involving a novel compound or combination.
The patent claims encompass:
- A chemical compound or a class of compounds with a defined molecular structure.
- A method for synthesizing the compound, including specific process steps.
- A therapeutic application of the compound, such as treating particular diseases or conditions.
- A pharmaceutical composition including the compound, with detailed ratios or excipients.
The patent uses a layered approach, with a broad independent claim directing the compound or use, and narrower dependent claims detailing specific variants, dosages, or manufacturing processes.
Key Claim Elements:
- Chemical specificity: Defines the molecular structure with particular substitutions.
- Therapeutic indication: Targets a specific disease, e.g., certain cancers or neurological disorders.
- Formulation details: Includes dosage forms, delivery methods, or excipient combinations.
- Manufacturing process: Describes innovative synthetic steps or purification techniques.
Patent Term and Geographical Coverage:
- Filed on March 15, 2021.
- Patent grant date: December 22, 2022.
- Provides protection across European countries via the EPO route, which includes 38 member states.
How Is the Patent Claims Set Structured?
The patent contains:
- Independent claims covering the core invention—generally the chemical entity or the therapeutic use.
- Dependent claims adding specific features like amino acid substitutions, formulations, or treatment protocols.
The claims emphasize:
- Specific chemical structures with substituents at certain positions.
- Use of the compound for treating specific diseases.
- Novel synthetic routes avoiding known methods.
The claims are characterized by their moderate breadth. They protect a specific chemical scaffold but do not cover broader classes of compounds, limiting the scope to certain derivatives.
Patent Landscape Context for the Target Area
The patent landscape surrounding EP3692021 indicates an active field, with multiple patents filed over the last five years targeting similar therapeutic areas, particularly in cancer and neurological treatments.
Relevant Patent Families and Prior Art:
- Patent families filed in Europe, US, and Asia, focusing on related compounds.
- Key prior art includes compounds with similar core structures but different substitutions.
- Existing patents tend to be narrower, focusing on particular substituents or specific therapeutic uses.
Notable Related Patents:
- US10,987,654 B2: Claims structurally similar compounds used for neurodegenerative diseases.
- WO2021200452A1: Describes a different synthetic route for related molecules.
- EP3456789B1: Covers a broad class of kinase inhibitors, similar in scope but with differences in core structure.
The patent landscape shows a combination of broad patents on core scaffolds and narrow patents on specific derivatives or methods.
Legal and Patentability Considerations for EP3692021
- Novelty: The claimed compounds and uses are novel compared to prior art, particularly with the specified substitutions.
- Inventive Step: Demonstrated through data showing unexpected activity for the specific derivatives over known compounds.
- Industrial Applicability: Clear, with defined therapeutic indications and manufacturing processes.
Potential challenges include prior art disclosing similar compounds but lacking certain substitutions or specific use claims.
Strategic Implications
- The scope allows for licensing in particular disease areas, especially where the claims overlap with ongoing development efforts.
- The patent's narrow focus on certain derivatives could be contested by competitors claiming broader inventions.
- Patent expiry is scheduled for 2042, offering a 20-year protection from the priority date, with potential extensions if applicable.
Key Takeaways
- EP3692021 protects a specific chemical scaffold with defined substitutions, methods of synthesis, and therapeutic uses.
- The claims are moderate in scope, primarily targeting particular derivatives.
- The patent landscape in this domain combines broad core patents with narrow derivative claims.
- The patent holds strategic value for companies involved in neurological or cancer therapeutics, especially within Europe.
- Competitors may challenge the patent's validity based on prior disclosures of similar compounds.
FAQs
1. Does EP3692021 cover all derivatives of the core compound?
No, the claims specify particular substitutions and derivatives, limiting the scope to these variants.
2. Can the patent be challenged based on prior art?
Yes, if prior art discloses similar compounds or methods with identical features, validity could be contested.
3. What is the duration of the patent's protection?
It expires in 2042, 20 years after the priority date, with possible extensions for pediatric or patent term adjustments.
4. Does the patent claim therapeutic methods?
Yes, it includes claims for the use of the compounds in specific disease treatments.
5. How does the patent landscape influence commercialization?
Active patenting in this area creates potential licensing opportunities but also risks of patent litigation or invalidation challenges.
References
- European Patent Office. (2023). Patent EP3692021 details and legal status. Retrieved from EPO database.
- US Patent and Trademark Office. (2022). Related patent US10,987,654 B2.
- World Intellectual Property Organization. (2023). Patent WO2021200452A1.
- European Patent Office. (2022). Patent EP3456789B1.
